HC Wainwright Issues Pessimistic Outlook for PLX Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Analysts at HC Wainwright lowered their Q3 2027 earnings per share estimates for Protalix BioTherapeutics in a research report issued to clients and investors on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.03 per share for the quarter, down from their prior estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2027 earnings at $0.07 EPS and FY2027 earnings at $0.12 EPS.

Protalix BioTherapeutics Stock Up 1.9%

Shares of NYSE PLX opened at $2.14 on Wednesday. The business has a fifty day simple moving average of $2.16 and a two-hundred day simple moving average of $2.20. The firm has a market cap of $172.42 million, a PE ratio of -16.46 and a beta of -0.01. Protalix BioTherapeutics has a twelve month low of $1.32 and a twelve month high of $3.19.

Institutional Investors Weigh In On Protalix BioTherapeutics

Institutional investors have recently added to or reduced their stakes in the stock. R Squared Ltd purchased a new position in Protalix BioTherapeutics in the fourth quarter worth $26,000. SG Americas Securities LLC acquired a new position in shares of Protalix BioTherapeutics during the fourth quarter valued at about $31,000. Bank of America Corp DE lifted its position in Protalix BioTherapeutics by 364,766.7% during the 2nd quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock worth $32,000 after acquiring an additional 21,886 shares during the period. Marshall Wace LLP acquired a new stake in Protalix BioTherapeutics during the 4th quarter worth about $34,000. Finally, BNP Paribas Financial Markets lifted its position in Protalix BioTherapeutics by 126.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock worth $34,000 after acquiring an additional 8,498 shares during the period. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics (NYSE:PLX) is a clinical?stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost?effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high?quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.